Intravenous ferric carboxymaltose versus iron sucrose in the treatment of iron deficiency anaemia in patients with chronic renal failure undergoing haemodialysis: a randomised trial

2013 ◽  
Author(s):  
Nikolay Khasabov
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Iron Deficiency ◽  
Iron Deficiency Anaemia ◽  
Randomised Trial ◽  
Iron Sucrose ◽  
Ferric Carboxymaltose ◽  
Deficiency Anaemia

scholarly journals Comparative study of efficacy and safety of parenteral iron sucrose versus ferric carboxymaltose in treatment of postpartum iron deficiency anaemia

2021 ◽  
Vol 11 (1) ◽  
pp. 100
Author(s):  
Ganesh N. Dakhle ◽  
Mrunalini V. Kalikar ◽  
Rujuta P. Fuke ◽  
Anisha S. Parmarthi ◽  
Mrunalini K. Chokhandre
Keyword(s):  
Iron Deficiency ◽  
Serum Ferritin ◽  
Iron Deficiency Anaemia ◽  
Maximum Dose ◽  
Iron Sucrose ◽  
Ferric Carboxymaltose ◽  
Care Hospital ◽  
Deficiency Anaemia ◽  
Iron Stores ◽  
Parenteral Iron

Background: Postpartum anaemia often leads to multiple clinical complications in mother as well as infant and iron supplementation with parenteral iron is the preferred treatment modality. The present study was planned to compare the efficacy and tolerability of IV iron sucrose and IV ferric carboxymaltose in treatment of postpartum iron deficiency anaemia.Methods: This randomized, parallel, open label, prospective 4-weeks study was conducted from June 2019 to December 2020 in women with postpartum anaemia admitted to obstetrics and gynaecology inpatient department of a tertiary care hospital. Women with postpartum iron deficiency anaemia (N=60) were randomly divided into two groups; receiving Injection iron sucrose (N=30, maximum dose 500 mg) or Injection ferric carboxymaltose (N=30, maximum dose 500 mg). Change in haemoglobin and serum ferritin levels from baseline to the end of 2 and 4 weeks of treatment were evaluated.Results: The results showed early, sustained and significant increase in the haemoglobin levels in both the groups. However, the difference was not significant between groups (p=0.2). Evaluation of replenishment of iron stores (serum ferritin) showed improvement in both the groups, however in FCM group the rise was found to be significant (p<0.05).Conclusions: FCM in a lower dose of 500mg was found to be safe and effective in significantly improving haemoglobin concentration as well as in replenishing iron stores in patients with postpartum anaemia.

scholarly journals A comparative study of efficacy, safety and compliance of intravenous ferric carboxymaltose versus iron sucrose in the treatment of iron deficiency anaemia of pregnancy

2021 ◽  
Vol 8 (4) ◽  
pp. 448-453
Author(s):  
Vathsala Kamath ◽  
Naimisha Reddy ◽  
Nishita Shettian
Keyword(s):  
Iron Deficiency ◽  
Pregnant Women ◽  
Iron Deficiency Anaemia ◽  
Intravenous Iron ◽  
Post Treatment ◽  
Oral Iron ◽  
Iron Sucrose ◽  
Ferric Carboxymaltose ◽  
Third Trimester ◽  
Deficiency Anaemia

Iron deficiency is the most common cause of anaemia worldwide and is associated with significant maternal and fetal morbidity. Current options for treatment include oral iron supplementation which can be ineffective and poorly tolerated, intravenous iron which can be used in patients who are intolerant to or unresponsive to oral iron and red blood cell transfusions which carry an inherent risk because of which it should be avoided. Intravenous iron therapy may reduce the requirement for allogenic blood transfusion. Ferric carboxymaltose is a new intravenous iron formulation promising to be more effective and as safe as iron sucrose. It may even have a better compliance as it offers the administration of a much higher iron dosage at a time.The study was designed to compare the efficacy and safety of IV ferric carboxymaltose versus iron sucrose in the treatment of iron deficiency anaemia of pregnant women with moderate anaemia in the second and third trimester.A hospital based randomized prospective study was done from July 2013 to June 2015 in the department of Obstetrics and Gynaecology, A.J. Institute of Medical Sciences, Mangalore. Baseline haemoglobin, peripheral smear and serum ferritin levels were measured to diagnose iron deficiency anaemia. 60 pregnant women who met the inclusion criteria and who formed the study subjects were randomly allocated into two groups comprising of 30 in Group C (Received ferric carboxymaltose) and 30 in Group S (Received iron sucrose). Outcome was assessed by measuring haemoglobin 3 weeks after treatment and a comparison of the safety and efficacy between the two groups was made. In the present study the commonest age group was 21 to 30 years: 80% in group C and 73.3% in group S and mean age of the study population in group C and S was comparable (25.2±3.54 vs 24.8±4.58 years). The socio demographic characteristics, obstetric history, vitals and pretreatment haemoglobin were comparable in both the groups (p&#62;0.050). The post treatment haemoglobin levels in 63.3% of the women in group C compared to 46.7% in group S were found to be 11 or more and mean post treatment haemoglobin levels were comparable in group C and group S (11.016±0.789 vs 10.73±0.821 gm%; p=0.174). In the present study, post treatment mean increase in haemoglobin levels was noted between 2.0 to 2.5 gm% in 43.3% of the women in group C compared to 50.0% in group S. Ferric carboxymaltose administration in pregnant women in the second and third trimesters is well tolerated and is not associated with any clinical safety concerns. Both ferric carboxymaltose and iron sucrose have a comparable safety profile even when ferric carboxymaltose was administered in a much higher dosage compared to iron sucrose. Ferric carboxymaltose should be considered as the drug of choice, if i.v. iron treatment becomes necessary in the second or third trimester of pregnancy.

scholarly journals Efficacy and cost effectiveness of intravenous ferric carboxymaltose versus iron sucrose in adult patients with iron deficiency anaemia

PLoS ONE ◽  
2021 ◽  
Vol 16 (8) ◽  
pp. e0255104
Author(s):  
Ahmad Basha ◽  
Mohamed Izham Mohamed Ibrahim ◽  
Anas Hamad ◽  
Prem Chandra ◽  
Nabil E. Omar ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Iron Deficiency ◽  
Blood Cell ◽  
Iron Deficiency Anaemia ◽  
Iron Sucrose ◽  
Ferric Carboxymaltose ◽  
Base Case ◽  
Deficiency Anaemia ◽  
Surrogate Outcomes ◽  
Iv Iron

Background Iron deficiency anaemia (IDA) is a major health issues and common type of nutritional deficiency worldwide. For IDA treatment, intravenous (IV) iron is a useful therapy. Objective To determine the efficacy and cost-effectiveness (CE) of intravenous (IV) Ferric Carboxymaltose (FCM) versus IV Iron Sucrose (IS) in treating IDA. Data sources Electronic medical record i.e. Cerner® system. Target population Adults patients with iron deficiency anaemia. Time horizon A 12-month period (01/01/2018–31/12/2018). Perspective Hamad Medical Corporation (HMC, a public hospital). Intervention IV Ferric Carboxymaltose versus IV Iron Sucrose. Outcome measures With regard to responses to treatment i.e., efficacy of treatment with FCM & IS in IDA patients, hemoglobin (Hgb), ferritin, and transferrin saturation (TSAT) levels were the primary outcomes. Additionally, the researchers also collected levels of iron, platelet, white blood cell (WBC), red blood cell (RBC), mean corpuscular hemoglobin (MCH), and mean corpuscular volume (MCV). The costs i.e. resources consumed (obtained from NCCCR-HMC) and the CE of FCM versus IS were the secondary outcomes. Results of base-case analysis There was a significant improvement in Hgb, RBC and MCH levels in the IS group than the FCM group. The overall cost of IS therapy was significantly higher than FCM. The medication cost for FCM was approximately 6.5 times higher than IS, nonetheless, it is cheaper in terms of bed cost and nursing cost. The cost effectiveness (CE) ratio illustrated that FCM and IS were significantly different in terms of Hgb, ferritin and MCH levels. Further, Incremental Cost Effectiveness Ratio (ICER) indicated that further justifications and decisions need to be made for FCM when using Hgb, iron, TSAT, MCH and MCV levels as surrogate outcomes. Results of sensitivity analysis Not applicable. Limitations The study did not consider the clinical or humanistic outcome. Conclusions The higher cost of FCM versus IS can be offset by savings in healthcare personnel time and bed space. ICER indicated that further justifications and decisions need to be made for FCM when using Hgb, iron, TSAT, MCH and MCV levels as surrogate outcomes.

scholarly journals Aetiological and Clinical Pattern of Severe Anaemia in a Tertiary Care Hospital at Rajshahi, Bangladesh

KYAMC Journal ◽  
2017 ◽  
Vol 6 (2) ◽  
pp. 631-636
Author(s):  
Md Azizul Hoque ◽  
Khaleda Akhter ◽  
Md Daharul Islam ◽  
Syed Mohammad Monowar Ali ◽  
Md Zillur Rahman ◽  
...  
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Iron Deficiency ◽  
Iron Deficiency Anaemia ◽  
Tertiary Care ◽  
Severe Anaemia ◽  
Large Sample Size ◽  
Care Hospital ◽  
Deficiency Anaemia ◽  
Chronic Disorder

Background: Anaemia is a common health problem encountered in our day to day medical practice. It occurs in every age groups, in both sexes in every communities and all countries.Objective: To find out the aetiological pattern and clinical profile of severe anaemia for prompt diagnosis an droper management.Materials and Methods: The prospective study was carried out in different Medicine unit at Rajshahi Medical College Hospital (RMCH), Rajshahi on consecutive 100 hospital admitted patients having severe anaemia. All underwent routine and some special investigations for severe anaemia.Results: Peak age incidence was 20-29 years (38%) and sex incidence was male (68%). Most of the patients were farmers (38%). Common monthly income group was >2000-5000 (48%). Incidence of severe anaemia was aplastic (26%), leukaemia (24%), haemolytic (22%), anaemia of chronic disorder (10%), iron deficiency anaemia (9%) and anaemia of chronic renal failure (9%). Peak age incidence for aplastic anaemia was 20- 29 years (42.3%), for leukaemia 14-19 years 33.3%), for haemolytic anaemia 14-19 years (50%), for anaemia of chronic disorder 20-29 and 30-39 years (30% each), iron deficiency anaemia 40-49 years (44.5%) and for anaemia of chronic renal failure 30-39 years (33.3%).Conclusion: Multicentre study with large sample size is warrented to develop more insights about diagnosis and management of severe anaemia.KYAMC Journal Vol. 6, No.-2, Jan 2016, Page 631-636

Comparative study of efficacy of intravenous iron sucrose versus ferric carboxymaltose in the treatment of iron deficiency anaemia

2020 ◽  
Vol 4 (02) ◽  
pp. 39-43
Author(s):  
Huque Mahfuz ◽  
Mohammad Elias Hossain ◽  
Mohammed Mosleh Uddin ◽  
Mostafil Karim
Keyword(s):  
Iron Deficiency ◽  
Normal Saline ◽  
Iron Deficiency Anaemia ◽  
Intravenous Iron ◽  
Iron Sucrose ◽  
Iron Therapy ◽  
Ferric Carboxymaltose ◽  
Deficiency Anaemia ◽  
Parenteral Iron ◽  
The Mean

Background: Iron deficiency anaemia (IDA) is a common haematological complication with potentially serious clinical consequences that may require intravenous iron therapy. Parenteral iron therapy results faster and higher replenishment of iron stores and correction of Haemoglobin (Hb) levels with better compliance. The study was to compare the efficacy of intravenous ferric carboxymaltose with intravenous iron sucrose to treat iron deficiency anaemia. Methods: 188 patients were included in the study. 100 patients were given iron sucrose. After a 25 mg test dose on the first infusion only, this was given at a dose of 300 mg by intravenous infusion diluted in 100 ml of normal saline, every alternate day. 88 patients were treated with ferric carboxymaltose at a dose of 500 mg diluted in 100 ml of normal saline by intravenous infusion. Hb level and serum Ferritin of both groups were done before iron therapy and 3 weeks after iron therapy. Results: The mean±SD rise of haemoglobin concentration 3 weeks after iron therapy in iron sucrose group was 11.0±0.61 g/dL, while in ferric carboxymaltose group was 11.2±0.64 g/dL. The mean±SD ferritin 3 weeks after iron therapy in iron sucrose group was 76.0±14.28 ng/mL, while in ferric carboxymaltose group was 80.0±15.16 ng/mL. No serious adverse events were reported in either the ferric carboxymaltose group or iron sucrose group. Conclusions: Ferric carboxymaltose causes higher rise in Hb level as compared to parenteral iron sucrose.

Sign in / Sign up

Export Citation Format

Share Document